It is the single most common question we hear at the start of a medical weight loss consultation in Tarzana: which one is better — tirzepatide or semaglutide? Patients arrive having read the headlines, compared notes with a friend, and formed an opinion before they sit down. The honest answer is more useful than a winner and a loser. Both medications work. One produces more weight loss on average in head-to-head research. And the right choice for you depends on your medical history, your goals, your tolerance, and what you can realistically stay on for the long run.

Here is a clear, evidence-based comparison — what the drugs actually do, what the direct head-to-head trial found, how they are dosed, how they differ in FDA-approved uses, and how we help patients at Contour Medical Clinic in Tarzana decide between them.

The short answer

In the only large randomized trial that compared them directly for obesity, tirzepatide produced greater average weight loss than semaglutide over 72 weeks. That does not automatically make it the right medication for every person. Semaglutide has FDA-approved indications tirzepatide does not, and vice versa. Individual response varies widely, and the medication you tolerate well and can continue consistently will almost always outperform the one you abandon at week nine.

How the two medications actually work

Semaglutide: a GLP-1 receptor agonist

Semaglutide mimics GLP-1, a hormone your gut releases after eating. Activating the GLP-1 receptor slows how quickly the stomach empties, signals satiety to the brain, and improves the body's insulin response to a meal. Practically, most patients describe feeling full sooner, staying full longer, and losing much of the mental noise around food.

Tirzepatide: a dual GIP and GLP-1 receptor agonist

Tirzepatide acts on two incretin receptors rather than one. In addition to GLP-1, it activates the GIP receptor. Research characterizes tirzepatide as an imbalanced dual agonist — its affinity for the GIP receptor is comparable to that of the body's own GIP, while its activity at the GLP-1 receptor is roughly fivefold weaker than native GLP-1, and it engages that receptor in a way that produces less agonist-induced desensitization. The working hypothesis is that adding GIP signaling contributes to greater effects on appetite, insulin sensitivity, and fat metabolism than GLP-1 signaling alone.

If you want the full picture on either medication on its own, we have detailed guides to semaglutide and to tirzepatide.

What the head-to-head research shows

Most comparisons you read online are indirect — stacking results from separate trials with different participants and different study designs. SURMOUNT-5 was different. It was a phase 3b randomized trial that put the two medications against each other, and it was published in The New England Journal of Medicine in 2025 (Aronne LJ, Horn DB, le Roux CW, et al. N Engl J Med. 2025;393(1):26-36).

Who was studied: 751 adults with a mean age of 45, with obesity (BMI ≥30, or ≥27 with at least one obesity-related complication) and without diabetes, across 32 sites in the United States and Puerto Rico. Participants were randomized to the maximum tolerated dose of either tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg), injected once weekly.

What happened at 72 weeks:

• Body weight: a least-squares mean change of −20.2% with tirzepatide versus −13.7% with semaglutide (p<0.001) — an average of 22.8 kg versus 15.0 kg.
• Waist circumference: −18.4 cm with tirzepatide versus −13.0 cm with semaglutide (p<0.001).
• Reaching weight-loss thresholds: participants on tirzepatide were more likely to reach reductions of at least 10% through at least 25% of body weight.
• Tolerability: most adverse events were mild to moderate and clustered during dose escalation. Gastrointestinal side effects severe enough to cause participants to stop treatment occurred more often with semaglutide (5.6%) than with tirzepatide (2.7%).

One finding deserves more attention than it usually gets: in both treatment groups, weight loss was approximately 6% lower in men than in women. The trial enrolled a higher proportion of men (35%) than most obesity trials, which the authors suggest may explain why overall results ran slightly below earlier studies. It is a useful reminder that trial averages describe populations, not individuals — and that your own trajectory is something we measure rather than assume.

Brand names and FDA-approved uses are not interchangeable

The same molecule can carry different brand names depending on what it is approved to treat, which is a frequent source of confusion.

• Semaglutide is marketed as Wegovy for chronic weight management and as Ozempic for type 2 diabetes.
• Tirzepatide is marketed as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes.

Beyond weight management, the approved indications diverge:

• Wegovy is additionally approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who have obesity or overweight, and it is approved for chronic weight management in adolescents aged 12 and older. In 2026 the FDA also approved a higher-dose 7.2 mg formulation, Wegovy HD, for weight reduction and long-term weight maintenance in certain adults.
• Zepbound is additionally approved for moderate to severe obstructive sleep apnea in adults with obesity — an indication semaglutide does not carry.

These differences matter clinically. A patient with known cardiovascular disease and a patient with untreated sleep apnea may reasonably be steered toward different medications for reasons that have nothing to do with which one produces more pounds lost.

Eligibility and dosing: what treatment actually looks like

Wegovy is indicated for adults with an initial BMI of ≥30 kg/m² (obesity), or ≥27 kg/m² (overweight) in the presence of at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Both medications are once-weekly subcutaneous injections, and both start low and escalate slowly — the titration schedule is not a formality, it is the main reason side effects stay manageable.

Tirzepatide (Zepbound) titration

Per the FDA prescribing information, treatment begins at 2.5 mg once weekly. After four weeks, the dose increases to 5 mg once weekly, and may then be increased in 2.5 mg increments after at least four weeks at the current dose. Available strengths are 2.5, 5, 7.5, 10, 12.5, and 15 mg. The 2.5 mg dose is for initiation only and is not an approved maintenance dose; approved maintenance doses for weight reduction and long-term maintenance are 5, 10, or 15 mg once weekly, with a maximum of 15 mg.

Semaglutide (Wegovy) titration

Semaglutide follows its own stepwise escalation to a recommended maintenance dose of 2.4 mg once weekly. If 2.4 mg is not tolerated, the label allows a maintenance dose of 1.7 mg once weekly.

In practice, we hold patients at whatever dose is working. There is no clinical prize for reaching the maximum. If you are losing steadily and feeling well at 7.5 mg, that is the dose.

Side effects and safety considerations

The side effect profiles overlap heavily. The most common issues for both are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. They are typically worst in the days following a dose increase and improve as the body adapts. Slower titration, smaller meals, adequate protein, and adequate hydration all help — and for patients who struggle with hydration during escalation, mobile IV therapy can be a practical short-term support.

Both medications carry a boxed warning regarding thyroid C-cell tumors. In rodent studies, both semaglutide and tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; whether this translates to humans has not been determined. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is one of the specific reasons a real medical history — not a checkbox on a website — has to come before a prescription.

This article is educational and is not a substitute for individual medical advice. Whether either medication is appropriate for you is a decision to make with a licensed provider who has reviewed your history, medications, and labs.

So which one should you choose?

Rather than ranking the drugs, we work through a short list of questions with every patient:

• What does your medical history point toward? Established cardiovascular disease, obstructive sleep apnea, type 2 diabetes, thyroid history, pancreatitis history, and gallbladder history all influence the decision before efficacy is even discussed.
• How much total weight change are you targeting? A patient aiming for a 25% reduction and a patient aiming for 10% are not necessarily best served by the same medication or the same target dose.
• How have you tolerated things in the past? Patients with a history of significant GI sensitivity may benefit from a slower escalation regardless of which medication is chosen.
• What can you actually sustain? Coverage, availability, and cost vary by individual and change over time. The most effective plan is the one you can stay on. We review your specific options during your consultation.
• What is happening to your muscle? This is the question most often skipped, and it matters more than almost anything else on this list.

Why the medication is only half the plan

Rapid weight loss without attention to body composition can cost you lean mass — and lean mass is what protects your metabolic rate, your strength, and your ability to keep the weight off. That is why every medical weight loss patient at our Tarzana clinic gets an InBody body composition analysis, not just a number on a scale. Tracking fat mass and skeletal muscle mass separately tells us whether the plan is working or quietly working against you. We cover this in depth in our guide to protecting lean mass during GLP-1 treatment.

The same logic applies to comprehensive lab testing. Thyroid function, metabolic markers, lipids, and hormone levels shape both what we prescribe and how we adjust it. For some patients — particularly men with low testosterone or women navigating perimenopause — addressing hormone optimization alongside weight management changes results substantially. And because most patients eventually ask what happens after the weight comes off, we have written separately about stopping a GLP-1 and maintaining your results.

Frequently asked questions

Is tirzepatide always better than semaglutide?

No. Tirzepatide produced greater average weight loss in SURMOUNT-5, but averages hide substantial individual variation. Some patients respond very well to semaglutide and less well to tirzepatide. Approved indications, medical history, and tolerability all factor into the decision.

Can I switch from one to the other?

Switching between GLP-1 medications is done in clinical practice, but it is not a matter of swapping pens. Dosing does not translate one-to-one between the two drugs, and a switch requires a new titration plan and provider supervision. Bring it up at a follow-up visit rather than adjusting on your own.

How long before I see results?

Both medications escalate over months, and meaningful change accumulates gradually. In SURMOUNT-5, the primary results were measured at 72 weeks. Expect a long arc, not a fast one, and expect the first several weeks to be about tolerability rather than dramatic numbers.

Do I have to stay on it forever?

Obesity is treated as a chronic condition, and both medications are approved for long-term weight management. Some patients transition to a maintenance dose; some taper with a structured plan. What is well documented is that stopping without a plan is associated with weight regain — which is why maintenance strategy is part of the conversation from the beginning, not an afterthought.

Will I lose muscle?

Some lean mass loss accompanies any significant weight loss. How much depends on protein intake, resistance training, and rate of loss. It is measurable — which is exactly why we measure it.

Talk to a provider in Tarzana

Choosing between tirzepatide and semaglutide is not a decision to make from a comparison chart, including this one. It is a clinical decision that depends on your history, your labs, your body composition, and your goals — and it should be made with a provider who will follow you through titration and beyond.

Contour Medical Clinic offers physician-supervised medical weight loss in Tarzana, serving Encino, Woodland Hills, Sherman Oaks, and the wider San Fernando Valley. Schedule a medical weight loss consultation to review your options, your labs, and a plan built around your body rather than an average.

Written by: Contour Medical Clinic Editorial Team